Nano-X Imaging exec reports initial share holdings
Nano-X Imaging Ltd. executive Yahav Attias Gali filed an initial ownership report as Chief Corporate Resources officer.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
3
Rhea-AI Filing Summary
Nano-X Imaging Ltd. executive Yahav Attias Gali filed an initial ownership report as Chief Corporate Resources officer. The filing lists direct holdings of ordinary shares and stock options, including options over 6,500, 12,500 and 40,000 ordinary shares with exercise prices between $11.52 and $23.86 and expirations from 2031 to 2033. A footnote explains that certain ordinary shares represent restricted share units granted on February 5, 2026, vesting in two equal installments over 12 and 24 months.
Insider Trade Summary
5 transactions reported
Mixed
5 txns
Insider
Yahav Attias Gali
Role
Chief Corporate Resources
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| holding | Stock Option (right to buy ordinary shares) | -- | -- | -- |
| holding | Stock Option (right to buy ordinary shares) | -- | -- | -- |
| holding | Stock Option (right to buy ordinary shares) | -- | -- | -- |
| holding | Ordinary shares | -- | -- | -- |
| holding | Ordinary shares | -- | -- | -- |
Holdings After Transaction:
Stock Option (right to buy ordinary shares) — 59,000 contracts (Direct);
Ordinary shares — 59,474 shares (Direct)
Footnotes (4)
- F1. The ordinary shares reported in this row consist of shares underlying restricted share units that were granted to the Reporting Person on February 5, 2026, of which 50% will vest on the 12-month anniversary of the grant date and the remaining 50% will vest on the 24-month anniversary of the grant date.
- F2. The options reported in this row were granted to the Reporting Person by the Issuer on September 30, 2021 and are fully vested and exercisable as of the date of this report.
- F3. The options reported in this row were granted to the Reporting Person by the Issuer on March 28, 2022 and vest and become exercisable in 16 equal quarterly installments of 6.25% each on each three-month anniversary of the grant date, such that all options reported in this row will be exercisable by the four-year anniversary of the grant date (March 28, 2026).
- F4. The options reported in this row were granted to the Reporting Person by the Issuer on May 23, 2023 and vest and become exercisable in 16 equal quarterly installments of 6.25% each on each three-month anniversary of the grant date, such that all options reported in this row will be exercisable by the four-year anniversary of the grant date (May 23, 2027).
Key Figures
Stock options @ $23.86: 6,500 underlying shares at $23.86
Stock options @ $17.63: 12,500 underlying shares at $17.63
Stock options @ $11.52: 40,000 underlying shares at $11.52
+3 more
6 metrics
Stock options @ $23.86
6,500 underlying shares at $23.86
Exercise price and size of one option grant, expiring 2031
Stock options @ $17.63
12,500 underlying shares at $17.63
Exercise price and size of one option grant, expiring 2032
Stock options @ $11.52
40,000 underlying shares at $11.52
Exercise price and size of one option grant, expiring 2033
Ordinary shares holding 1
20,000 ordinary shares
Direct ordinary share position as reported in Form 3
Ordinary shares holding 2
39,474 ordinary shares
Additional direct ordinary share position as reported in Form 3
RSU vesting schedule
50% at 12 months, 50% at 24 months
Restricted share units granted February 5, 2026 vest in two tranches
Key Terms
Stock Option (right to buy ordinary shares), restricted share units, fully vested and exercisable, vest and become exercisable in 16 equal quarterly installments, +1 more
5 terms
fully vested and exercisable financial
"were granted ... and are fully vested and exercisable as of the date"
vest and become exercisable in 16 equal quarterly installments financial
"vest and become exercisable in 16 equal quarterly installments of 6.25%"
beneficial ownership financial
"initial statement of beneficial ownership of securities (Form 3 context)"
Beneficial ownership means the person or entity that actually enjoys the benefits of owning shares or other assets — such as receiving dividends, voting rights, or price gains — even if the legal title is held in another name. For investors it matters because knowing who truly controls and profits from a company reveals who can influence decisions, exposes potential conflicts of interest or hidden concentration of power, and affects transparency and risk in the stock.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What does Nano-X Imaging (NNOX) report in this Form 3 filing?
Nano-X Imaging executive Yahav Attias Gali reports initial ownership of ordinary shares and stock options. The filing lists direct holdings in common stock plus several option grants with specified exercise prices, share amounts, and long-dated expiration schedules, establishing his baseline stake as an officer.
How many Nano-X Imaging options does Yahav Attias Gali hold?
The Form 3 shows stock options linked to 6,500, 12,500 and 40,000 ordinary shares. These options carry exercise prices of $23.86, $17.63 and $11.52 respectively and expire between September 2031 and May 2033, giving long-term potential equity exposure if exercised.
Are the Nano-X Imaging options reported in this Form 3 already exercisable?
One option grant, issued September 30, 2021, is described as fully vested and exercisable as of the report date. Two later grants from March 28, 2022 and May 23, 2023 vest in 16 equal quarterly installments, becoming fully exercisable by March 28, 2026 and May 23, 2027, respectively.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Accepted by SEC EDGAR
Learn about SEC filing dates